Högskolan i Skövde

his.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • apa-cv
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood brain barrier research in a pharmaceutical setting
Microphysiological Systems Center of Excellence, Drug Safety & Metabolism, IMED Biotech Unit, AstraZeneca, Waltham, MA, United States.
Högskolan i Skövde, Institutionen för biovetenskap. Högskolan i Skövde, Forskningscentrum för Systembiologi. Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden / Institute of Neuroscience and Physiology, Department of Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. (Bioinformatik, Bioinformatics)ORCID-id: 0000-0003-2899-3801
Discovery Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
Vise andre og tillknytning
2019 (engelsk)Inngår i: Advanced Drug Delivery Reviews, ISSN 0169-409X, E-ISSN 1872-8294, Vol. 140, s. 129-135Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Microphysiological systems (MPS) may be able to provide the pharmaceutical industry models that can reflect human physiological responses to improve drug discovery and translational outcomes. With lack of efficacy being the primary cause for drug attrition, developing MPS disease models would help researchers identify novel targets, study mechanisms in more physiologically-relevant depth, screen for novel biomarkers and test/optimize various therapeutics (small molecules, nanoparticles and biologics). Furthermore, with advances in inducible pluripotent stem cell technology (iPSC), pharmaceutical companies can access cells from patients to help recreate specific disease phenotypes in MPS platforms. Combining iPSC and MPS technologies will contribute to our understanding of the complexities of neurodegenerative diseases and of the blood brain barrier (BBB) leading to development of enhanced therapeutics. © 2018

sted, utgiver, år, opplag, sider
Elsevier, 2019. Vol. 140, s. 129-135
Emneord [en]
Blood brain barrier, Drug development, iPSC, Microphysiological systems, Organs-on-chips, Pharmaceutical, Stem cells, Tissue chips, Blood, Drug products, Neurodegenerative diseases, Blood-brain barrier, Induced pluripotent stem cells, On chips, Pharmaceutical company, Pharmaceutical industry, Physiological response, Physiological models
HSV kategori
Forskningsprogram
Bioinformatik; INF502 Biomarkörer
Identifikatorer
URN: urn:nbn:se:his:diva-16305DOI: 10.1016/j.addr.2018.09.009ISI: 000482251800010PubMedID: 30253201Scopus ID: 2-s2.0-85054095107OAI: oai:DiVA.org:his-16305DiVA, id: diva2:1256243
Tilgjengelig fra: 2018-10-16 Laget: 2018-10-16 Sist oppdatert: 2019-09-12bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Søk i DiVA

Av forfatter/redaktør
Delsing, Louise
Av organisasjonen
I samme tidsskrift
Advanced Drug Delivery Reviews

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 423 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • apa-cv
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf